Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 adaptive study of LAD191 in adults with moderate-to-severe hidradenitis suppurativa
2025-521293-34-00Phase 2Authorised
- Sponsor
- Almirall
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of ALM27134 in hidradenitis suppurativa (HS) (4 arms), sponsored by Almirall. Primary endpoints: Proportion of participants achieving HiSCR 50, Frequency and severity of treatment-emergent adverse events and 1 more. Planned start Dec 2025; status: authorised.
02
Drugs
ALM27134
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2025-521293-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521293-34-00.